Irritable Bowel Syndrome Treatment Market
Segments - by Types (Constipation-predominant [Linzess/Constella, Amitiza, and Others], Diarrhea-predominant [Xifaxan, Viberzi, and Others]), Products (Xifaxan, Linzess/Constella, Viberzi, Amitiza, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global irritable bowel syndrome treatment market size is anticipated to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the growing prevalence of target disease and rising uptake of drugs. In different regions commercialization of existing products is growing which drives the market. Rising acceptance of Linzess in the U.S., Japan, and Europe is contributing in the revenue growth.
Irritable bowel syndrome (IBS) is most common gastrointestinal disorder affecting large intestine, with prevalence rate of around 10-12%, globally. Symptoms and signs include bloating, cramping, gas, constipation, abdominal pain, and diarrhea. Irritable bowel syndrome treatment includes change in diet, counselling, stress relief, and proper medicines. The particular cause of symptoms is indefinite but it may disturb interaction between brain, nervous system, and gut. Due to this, changes occur in bowel sensation and movement. Based on survey conducted by the International Foundation for Gastrointestinal Disorders (IFFGD), around 2,050 IBS patients said that diagnosis of their conditions was completed 6.6 years after their symptoms initiated.
The market is neglected, with large number of opportunities for pharmaceutical companies to talk about numerous unmet needs in the therapy. Under clinical trials there are some promising products which increases the speed of the growth. Product sales are anticipated to raise considerably during the forecast period, majorly owing to growing prevalent population and commercialization of novel drugs for the treatment of constipation-predominant IBS.
Around 25-45% of patients take appointment of gastroenterologists because of symptoms of IBS. Still huge number of people are undiagnosed and unconscious about their symptoms which shows a medically known disorder. Because of this, various awareness campaigns are need to be organized to increase awareness about the condition. For instance, in April 2018, in the U.K., The IBS network conducted various activities to overcome the stigma about illness.
Market Trends, Drivers, Restraints, and Opportunities
- Growing geriatric population and increasing prevalence of gastrointestinal diseases are major factors responsible for the market growth in coming years.
- Rising awareness about treatment and management of IBS among people and increasing inclination towards irritable bowel syndrome products are expected to fuel the market expansion during the forecast period.
- Increasing prevalence of disorders including abdominal pain and bowel habit, unhealthy diet, and surge in level of stress is projected to drive the growth of the market.
- Untapped potential present in emerging economies, sedentary lifestyle, and launched of several developed pipeline drugs for IBS treatment are anticipated to boost the market growth over the forecast period.
- Lack of specific treatment which treat all symptoms of IBS is key factor that can hamper the market expansion during the forecast period.
- Huge competition among major market players associated with pricing is projected to impede the market growth.
Scope of the Report
The report on the global irritable bowel syndrome treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Irritable Bowel Syndrome Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Types (Constipation-predominant [Linzess/Constella, Amitiza, and Others], Diarrhea-predominant [Xifaxan, Viberzi, and Others]), Products (Xifaxan, Linzess/Constella, Viberzi, Amitiza, and Others) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Ironwood Pharmaceuticals, Inc., Allergan, Astellas Pharma, Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synergy Pharmaceuticals Inc., Bausch Health, Synthetic Biologics, Inc., and Ardelyx |
Market Segment Insights
IBS-C segment is expected to grow at a rapid pace
Based on types, the irritable bowel syndrome treatment market is divided into constipation-predominant (IBS-C) and diarrhea-predominant (IBS-D). The IBS-C segment is subdivided into linzess/constella, amitiza, and others. Also, the IBS-D segment is subdivided into xifaxan, viberzi, and others.
The IBS-C segment accounted for key share of the market due to growing prevalence of target diseases and increasing uptake of drugs including Linzess/Constella and Amitiza. Moreover, the segment is anticipated to expand at a rapid pace during the forecast period owing to projected launch of products such as Tenapanor and SYN-010. These products are presently under clinical trials. Astellas Pharma, AstraZeneca, Ironwood Pharmaceuticals, Inc., and Allergan are some key players present in this segment.
Linzess/Constella segment is projected to hold a key market share
On the basis of products, the irritable bowel syndrome treatment market is segmented into xifaxan, linzess/constella, viberzi, amitiza, and others. The linzess/constella (linaclotide) segment is expected to hold a key share of the market during the forecast period owing to growing adoption of products in major regions including Japan, the U.S., Germany, UK, Italy, and Spain. In the U.S., Ironwood and Allergan marketed Linaclotide as a Linzess and in Europe Linaclotide is marketed as Constella by Allergan.
North America is expected to dominate the market
On the basis of regions, the irritable bowel syndrome treatment market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is expected to exhibit a rapid growth rate in the coming years owing to existence of major market players, larger awareness among patients, huge presence of novel products, and well-established healthcare infrastructure.
On the other hand, the market of Europe is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to increasing commercialization of IBS products, growing initiatives to increase awareness about disorder among people, and presence of a large target population.
Segments
Segments Covered in the ReportThe global irritable bowel syndrome treatment market has been segmented on the basis of
Types
- Constipation-predominant (IBS-C)
- Linzess/Constella
- Amitiza
- Others
- Diarrhea-predominant (IBS-D)
- Xifaxan
- Viberzi
- Others
- Xifaxan
- Linzess/Constella
- Viberzi
- Amitiza
- Others
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Ironwood Pharmaceuticals, Inc.
- Allergan
- Astellas Pharma, Inc.
- Takeda Pharmaceutical Company Limited
- AstraZeneca
- Sebela Pharmaceuticals Inc.
- Synergy Pharmaceuticals Inc.
- Bausch Health,
- Synthetic Biologics, Inc.
- Ardelyx
Competitive Landscape
Key players competing in the irritable bowel syndrome treatment market are Ironwood Pharmaceuticals, Inc., Allergan, Astellas Pharma, Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synergy Pharmaceuticals Inc., Bausch Health, Synthetic Biologics, Inc., and Ardelyx.
Major market players are adopting several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance, in April 2015, Salix Pharmaceuticals was acquired by Bausch Health for expansion of its portfolio by focusing on gastrointestinal drugs. Also, in January 2019, AstraZeneca and Ironwood Pharmaceuticals got marketing approval of Linzess in China to make stronger position in the market.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Irritable Bowel Syndrome Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Irritable Bowel Syndrome Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Irritable Bowel Syndrome Treatment Market - Supply Chain
4.5. Global Irritable Bowel Syndrome Treatment Market Forecast
4.5.1. Irritable Bowel Syndrome Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Irritable Bowel Syndrome Treatment Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Irritable Bowel Syndrome Treatment Market Absolute $ Opportunity
5. Global Irritable Bowel Syndrome Treatment Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Types
5.3.1. Constipation-predominant (IBS-C) Linzess/Constella Amitiza Others Diarrhea-predominant (IBS-D)
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Irritable Bowel Syndrome Treatment Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Irritable Bowel Syndrome Treatment Demand Share Forecast, 2019-2026
7. North America Irritable Bowel Syndrome Treatment Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Types
7.4.1. Constipation-predominant (IBS-C) Linzess/Constella Amitiza Others Diarrhea-predominant (IBS-D)
7.5. Basis Point Share (BPS) Analysis by Types
7.6. Y-o-Y Growth Projections by Types
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Irritable Bowel Syndrome Treatment Demand Share Forecast, 2019-2026
8. Latin America Irritable Bowel Syndrome Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Types
8.4.1. Constipation-predominant (IBS-C) Linzess/Constella Amitiza Others Diarrhea-predominant (IBS-D)
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Irritable Bowel Syndrome Treatment Demand Share Forecast, 2019-2026
9. Europe Irritable Bowel Syndrome Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Types
9.4.1. Constipation-predominant (IBS-C) Linzess/Constella Amitiza Others Diarrhea-predominant (IBS-D)
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Irritable Bowel Syndrome Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Irritable Bowel Syndrome Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Types
10.4.1. Constipation-predominant (IBS-C) Linzess/Constella Amitiza Others Diarrhea-predominant (IBS-D)
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Irritable Bowel Syndrome Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Irritable Bowel Syndrome Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Types
11.4.1. Constipation-predominant (IBS-C) Linzess/Constella Amitiza Others Diarrhea-predominant (IBS-D)
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Irritable Bowel Syndrome Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Irritable Bowel Syndrome Treatment Market: Market Share Analysis
12.2. Irritable Bowel Syndrome Treatment Distributors and Customers
12.3. Irritable Bowel Syndrome Treatment Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Ironwood Pharmaceuticals, Inc.
12.4.2. Allergan
12.4.3. Astellas Pharma, Inc.
12.4.4. Takeda Pharmaceutical Company Limited
12.4.5. AstraZeneca
12.4.6. Sebela Pharmaceuticals Inc.
12.4.7. Synergy Pharmaceuticals Inc.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Irritable Bowel Syndrome Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Irritable Bowel Syndrome Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Irritable Bowel Syndrome Treatment Market - Supply Chain
4.5. Global Irritable Bowel Syndrome Treatment Market Forecast
4.5.1. Irritable Bowel Syndrome Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Irritable Bowel Syndrome Treatment Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Irritable Bowel Syndrome Treatment Market Absolute $ Opportunity
5. Global Irritable Bowel Syndrome Treatment Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Types
5.3.1. Constipation-predominant (IBS-C) Linzess/Constella Amitiza Others Diarrhea-predominant (IBS-D)
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Irritable Bowel Syndrome Treatment Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Irritable Bowel Syndrome Treatment Demand Share Forecast, 2019-2026
7. North America Irritable Bowel Syndrome Treatment Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Types
7.4.1. Constipation-predominant (IBS-C) Linzess/Constella Amitiza Others Diarrhea-predominant (IBS-D)
7.5. Basis Point Share (BPS) Analysis by Types
7.6. Y-o-Y Growth Projections by Types
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Irritable Bowel Syndrome Treatment Demand Share Forecast, 2019-2026
8. Latin America Irritable Bowel Syndrome Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Types
8.4.1. Constipation-predominant (IBS-C) Linzess/Constella Amitiza Others Diarrhea-predominant (IBS-D)
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Irritable Bowel Syndrome Treatment Demand Share Forecast, 2019-2026
9. Europe Irritable Bowel Syndrome Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Types
9.4.1. Constipation-predominant (IBS-C) Linzess/Constella Amitiza Others Diarrhea-predominant (IBS-D)
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Irritable Bowel Syndrome Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Irritable Bowel Syndrome Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Types
10.4.1. Constipation-predominant (IBS-C) Linzess/Constella Amitiza Others Diarrhea-predominant (IBS-D)
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Irritable Bowel Syndrome Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Irritable Bowel Syndrome Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Irritable Bowel Syndrome Treatment Market Size and Volume Forecast by Types
11.4.1. Constipation-predominant (IBS-C) Linzess/Constella Amitiza Others Diarrhea-predominant (IBS-D)
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Irritable Bowel Syndrome Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Irritable Bowel Syndrome Treatment Market: Market Share Analysis
12.2. Irritable Bowel Syndrome Treatment Distributors and Customers
12.3. Irritable Bowel Syndrome Treatment Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Ironwood Pharmaceuticals, Inc.
12.4.2. Allergan
12.4.3. Astellas Pharma, Inc.
12.4.4. Takeda Pharmaceutical Company Limited
12.4.5. AstraZeneca
12.4.6. Sebela Pharmaceuticals Inc.
12.4.7. Synergy Pharmaceuticals Inc.
Our Clients
Related Reports
Some other reports from this category!
